Erlotinib/osimertinib/rociletinibAcquired drug resistance in metastatic lung adenocarcinoma: case report

被引：0

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1693卷 / 1期

关键词：

D O I：

10.1007/s40278-018-43090-y

中图分类号：

学科分类号：

摘要：

引用

页码：200 / 200

共 50 条

[1] Erlotinib/osimertinib/rociletinibAcquired osimertinib resistance and various other toxicities: case report
[J]. Reactions Weekly, 2019, 1780 (1) : 155 - 155
[2] ErlotinibDevelopment of drug resistance in metastatic lung adenocarcinoma: case report
[J]. Reactions Weekly, 2018, 1723 (1) : 138 - 138
[3] Erlotinib/osimertinibDevelopment of resistance in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2019, 1765 (1) : 158 - 158
[4] Erlotinib/osimertinibDevelopment of resistance in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2019, 1749 (1) : 180 - 180
[5] OsimertinibAcquired resistance to osimertinib therapy in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2018, 1718 (1) : 176 - 176
[6] Erlotinib/osimertinibDevelopment of resistance in advanced lung adenocarcinoma: case report
[J]. Reactions Weekly, 2019, 1781 (1) : 160 - 160
[7] Osimertinib/gefitinib/erlotinibDevelopment of resistance to osimertinib, gefitinib and erlotinib: case report
[J]. Reactions Weekly, 2017, 1654 (1) : 269 - 269
[8] EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
von Buttlar, Xinyu
Reuss, Joshua E.
V. Liu, Stephen
Kim, Chul
[J]. JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
[9] Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: A case report
Sakhri L.
Meynet E.
Ferrer L.
Pirvu A.
Ferretti G.
Moro-Sibilot D.
[J]. Journal of Medical Case Reports, 8 (1)
[10] Erlotinib/mycophenolate mofetil/tacrolimusSkin toxicity following drug interaction and metastatic lung adenocarcinoma: case report
[J]. Reactions Weekly, 2018, 1729 (1) : 113 - 113

← 1 2 3 4 5 →